Lenskart sees runway to grow India network from 2,500 to 7,000 stores, resurfacing HSBC's April coverage
Resurfacing an April call, HSBC had initiated coverage on Lenskart with a Hold rating and ₹513 target, citing limited near-term upside despite the eyewear retailer's expansion potential. The broker pointed to sub-one-year store payback, supply-chain integration and omnichannel demand as supports for a much larger India footprint.
What happened
HSBC initiated Lenskart with a Hold and Rs 513 target, citing valuation despite strong execution. The eyewear retailer plans potential expansion to 7,000 India
Key facts
- HSBC target price: Rs 513
- Implied upside: about 2%
- India organised eyewear market share: about 20%
- Expected eyewear market annual growth: around 13%
- Current India stores: about 2,500
- Potential India store count: around 7,000
- Store payback period: less than one year
Why this matters
Lenskart’s planned national scale-up underscores the value of supply-chain capabilities, local market access and omnichannel partnerships in accelerating eyewear retail expansion.
What to watch
- Quarterly net store additions versus the pace required to reach 7,000 locations.
- New-store payback period, mature-store sales productivity and same-store sales growth.
- Gross-margin and EBITDA-margin trends as store mix shifts toward smaller cities.
- Inventory turns, fulfillment lead times and lab capacity utilization.
- Evidence of cannibalization in dense urban clusters.
- Consumer demand trends for discretionary eyewear and premium lens upgrades.
- Competitor store openings, discounting and online customer-acquisition costs.
- Prioritize clusters around existing labs, warehouses and high-performing stores to lower fulfillment and marketing costs.
- Use store-level payback, same-store sales and repeat-purchase data to gate expansion by city rather than pursue a uniform rollout.
- Expand eye-test, subscription, insurance and lens-upgrade attachment rates to raise revenue per customer as footprint scales.
- Build smaller-format and franchise-like models selectively for lower-density markets while retaining control of clinical quality and inventory.